Luoxin pharmaceutical: fosapitam for injection and meglumine have obtained the drug registration certificate
Luoxin pharmaceutical announced that Shandong Luoxin, a subsidiary of the company, recently received the drug registration certificate of fosapitam meglumine for injection approved and issued by the State Drug Administration. The drug registration certificate of fosapitam meglumine for injection is deemed to have passed the consistency evaluation, which will improve the market competitiveness of the company in the field of anti-tumor and further enrich the company's product line.
This text is a result of machine translation.
Related companies：
Briefing Jun 10, 2022 09:48 PM
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
Briefing Jun 10, 2022 07:17 PM
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
In-depth
Briefing May 20, 2022 09:04 AM
· Industrials
It is still difficult to find a car after continuous price increases. Now it takes two or three more months to buy a new energy vehicle
Jan 30, 2026 06:00 PM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Briefing Apr 28, 2022 09:59 AM
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
Jingdong supermarket is expected to continue to supply 1600 tons of rice noodles by the end of April
Briefing Mar 11, 2022 10:59 AM
· Financials
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
Briefing Feb 28, 2022 08:18 PM
Monetary Policy Department of the central bank: China has the ability and conditions to effectively respond to external shocks and domestic downward pressure
Briefing Feb 25, 2022 08:48 PM
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
Briefing Feb 15, 2022 06:19 AM
· Automotive
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
See more
Read next
Insight
In-depth
Automotive · Analysis
Investment Is Booming, Orders Are Rising, but Robots Are Still Learning How to Deliver
Mar 23, 2026 10:29 AM
Insight
In-depth
Automotive · Analysis
Thinking of ASEAN as a single market is the biggest miscalculation for Chinese companies
Feb 19, 2026 12:00 PM
Insight
In-depth
Consumer Staples, Industrials, Communication
You're Invited: China's Innovation, Up Close
Feb 10, 2026 04:21 PM
Insight
In-depth
Automotive · Analysis
CES 2026 in Numbers | From Shenzhen to Las Vegas: Huaqiangbei’s Year-End Report
Jan 15, 2026 09:42 PM